The crosstalk between probiotics and T cell immunity

Yuanyuan Liu, Xu Cao, Hongwei Liu, Wencan ZhangFrontiers in Immunology 2025 · DOI

This review paper, published in Frontiers in Immunology, synthesizes current research on the "probiotics-T cell axis." It moves beyond the general idea of "gut health" to detail the specific molecular conversations between probiotic bacteria and the adaptive immune system, offering a roadmap for using microbes to treat autoimmunity and enhance cancer therapy.

TL;DR

The paper explores how probiotics and their metabolites (like SCFAs and indole derivatives) orchestrate the differentiation and function of CD4+ and CD8+ T cells. By modulating the balance between pro-inflammatory and regulatory immune responses, probiotics are transitioning from simple dietary supplements to sophisticated tools for precision medicine and "smart" cancer immunotherapy.

What Problem Does This Paper Address?

While the general health benefits of probiotics are widely accepted, the specific molecular mechanisms by which they influence the adaptive immune system—particularly T cells—have remained fragmented. T cells are the "generals" of the immune system, deciding whether to attack (inflammation) or stand down (tolerance).

The authors address the challenge of immune dysregulation. In autoimmune diseases, the system is overactive; in cancer, it is often too suppressed. This paper seeks to answer: How can we use specific microbial strains to "tune" T cell responses to either suppress chronic inflammation or jumpstart an anti-tumor attack?

Methods

As a comprehensive review, the authors synthesized mechanistic findings from in vitro experiments, animal models (primarily murine), and human clinical trials. They categorized the "crosstalk" into three main functional areas:

  1. Developmental: How maternal and early-life probiotic exposure shapes the neonatal T cell repertoire.
  2. Regulatory (CD4+): How microbes influence the Th17/Treg balance to manage inflammatory diseases like colitis and osteoporosis.
  3. Effector (CD8+): How microbes enhance the "killing" power and infiltration of T cells within the tumor microenvironment.
  4. Synthetic Biology: An evaluation of "engineered probiotics"—using bacteria as delivery vehicles for therapeutic payloads.

Datasets

The paper does not introduce a new dataset; instead, it provides a meta-analysis of over 110 primary research articles. A key contribution is Table 1, which serves as a curated benchmark, listing specific probiotic strains (e.g., Lactobacillus plantarum L168, Bifidobacterium pseudolongum), their molecular targets (e.g., H3K27ac binding, TLR5 signaling), and the resulting clinical or physiological effects.

Key Insights and Ideas

  • The Metabolite Messenger: The crosstalk isn't just about the bacteria themselves, but their "secretome." Short-chain fatty acids (SCFAs) and tryptophan metabolites (like indole-3-lactic acid) act as signaling molecules that directly alter T cell gene expression via epigenetic modifications.
  • The Th17/Treg Seesaw: A major "aha moment" is the ability of specific strains to tip the scales. For instance, L. intestinalis can downregulate the pro-inflammatory transcription factor RORγt (reducing Th17 cells) while upregulating Foxp3 (increasing suppressive Treg cells), effectively "cooling down" an overactive immune system in colitis.
  • Priming the "Killers": In cancer, probiotics like L. reuteri release metabolites that stimulate IFNγ production in CD8+ T cells, preventing them from becoming "exhausted" and helping them infiltrate solid tumors more effectively.
  • Maternal Imprinting: Probiotic supplementation during pregnancy can alter DNA methylation patterns in the offspring’s T cells, potentially providing long-term protection against viral infections or allergies from birth.

Key Results

  • Enhanced Immunotherapy: Probiotics were shown to significantly boost the efficacy of Immune Checkpoint Inhibitors (like anti-PD-1/CTLA-4). For example, L. gallinarum inhibits the IDO1/Kyn/AHR axis, which normally helps tumors hide from the immune system.
  • Engineered Precision: The paper highlights a study where engineered E. coli Nissle 1917 was used to increase intratumoral L-arginine. This metabolic shift expanded the population of tumor-infiltrating T cells and synergized with PD-L1 antibodies to clear tumors in mice.
  • Tissue-Resident Memory: Supplementation with B. pseudolongum was found to drive the differentiation of CD8+ tissue-resident memory T cells (TRM), which are crucial for long-term surveillance and preventing cancer recurrence.

Limitations and Future Work

  • Strain Specificity: The authors emphasize that probiotic benefits are "highly strain-specific." A result seen with one Lactobacillus strain cannot be assumed for another, making clinical standardization difficult.
  • The Safety Paradox: While probiotics are generally safe (GRAS), their use in severely immunocompromised cancer patients carries a risk of microbial translocation and sepsis.
  • Human Translation: Much of the mechanistic "crosstalk" has been mapped in mice. The authors call for more large-scale human clinical trials to account for the massive variability in individual human gut microbiomes.
  • Scaling Synthetic Biology: While engineered "smart microbes" show promise in the lab, scaling the production and ensuring the stability of these genetically modified organisms in the human gut remains a significant engineering hurdle.

Summary updated

Abstract

Probiotic supplementation is one of the most widely well-recognized approaches for health maintaining. Distinct probiotics have been experimentally and mechanically investigated for their possible effectiveness in treating autoimmune disease, metabolic diseases, and cancer immune therapy, showing extensive and promising therapeutic potential. Focusing on the T cell mediated responses and diseases, this review specifically aims to elucidate the intricate crosstalk between probiotic microorganisms and T cells, exploring how probiotics modulate the differentiation, activation, proliferation, and functional states of different T cell subsets, such as CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells, thereby influencing the overall immune response and immune homeostasis. By revealing this crosstalk, we aim to uncover the potential of probiotics in immune regulation and disease prevention, providing valuable insights for developing novel therapeutic strategies and preventive measures leveraging the probiotics-T cell axis.
BibTeX
@inproceedings{liu2025crosstalk,
  author = {Yuanyuan Liu and Xu Cao and Hongwei Liu and Wencan Zhang},
  title = {{The crosstalk between probiotics and T cell immunity}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1695840},
}
Figure